Pacira BioSciences (PCRX) Cash from Financing Activities (2010 - 2026)
Pacira BioSciences (PCRX) posted quarterly Cash from Financing Activities of -$59.4 million for Q1 2026, down 1883.9% year-over-year from $3.3 million in Q1 2025, and down 15.0% quarter-over-quarter from -$51.7 million in Q4 2025.
Pacira BioSciences (PCRX) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Pacira BioSciences' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at -$59.4 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 1883.9% year-over-year to -$59.4 million; the TTM figure through Mar 2026 stood at -$426.0 million (down 2578.94% YoY), while the FY2025 annual figure was -$369.6 million, down 2228.82% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$59.4 million, down from -$51.7 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $25.0 million in Q2 2024, with the low at -$257.5 million in Q3 2025.
- The 5-year median for Cash from Financing Activities is -$27.8 million (2023), against an average of -$58.6 million.
- The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities soared 5577.27% in 2024, then slumped 8950.12% in 2025.
- Pacira BioSciences' Cash from Financing Activities stood at -$58.5 million in 2022, then surged by 96.96% to -$1.8 million in 2023, then dropped by 9.89% to -$2.0 million in 2024, then slumped by 2542.05% to -$51.7 million in 2025, then declined by 15.0% to -$59.4 million in 2026.
- Business Quant data shows PCRX's Cash from Financing Activities at -$59.4 million in Q1 2026, -$51.7 million in Q4 2025, and -$257.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Pacira BioSciences | 970.37 Mn | 719.34 Mn | 148.24 Mn | -7.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.65 Mn |
| Jun 30, 2026 | -7.65 Mn |
| Mar 31, 2026 | -59.40 Mn |
| Mar 31, 2026 | -59.40 Mn |
| Dec 31, 2025 | -51.65 Mn |
| Dec 31, 2025 | -51.65 Mn |
| Sep 30, 2025 | -257.48 Mn |
| Sep 30, 2025 | -257.48 Mn |
| Jun 30, 2025 | -57.51 Mn |
| Jun 30, 2025 | -57.51 Mn |
| Mar 31, 2025 | -2.99 Mn |
| Mar 31, 2025 | -2.99 Mn |
| Dec 31, 2024 | -1.96 Mn |
| Dec 31, 2024 | -1.96 Mn |
| Sep 30, 2024 | -2.85 Mn |
| Sep 30, 2024 | -2.85 Mn |
| Jun 30, 2024 | 24.98 Mn |
| Jun 30, 2024 | 24.98 Mn |
| Mar 31, 2024 | -2.82 Mn |
| Mar 31, 2024 | -2.82 Mn |